Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors
The ability to detect minimal residual disease (MRD) after a curative-intent surgery or treatment is of paramount importance, because it offers the possibility to help guide the clinical decisions related adjuvant therapy. Thus, the earlier MRD is detected, the earlier potentially beneficial treatme...
Guardado en:
Autores principales: | Lionel Larribère, Uwe M. Martens |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/b8daf264d4a245bcae974b1bd6f1accc |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Liquid Biopsy to Detect Minimal Residual Disease: Methodology and Impact
por: Natasha Honoré, et al.
Publicado: (2021) -
Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature
por: Klempner SJ, et al.
Publicado: (2017) -
Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer
por: Veldore VH, et al.
Publicado: (2018) -
Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives
por: Yan Peng, et al.
Publicado: (2021) -
BRCA1 promoter hypermethylation on circulating tumor DNA correlates with improved survival of patients with ovarian cancer
por: Maha Elazezy, et al.
Publicado: (2021)